Ambu A/s Class B · OMXCOP:AMBU_B
Ambu A/s Class B — Ambu A S Ord — Q3 2020/21 Earnings Presentation
21 slides from Ambu A/s Class B's earnings presentation, Aug 17, 2021
Slide 1: Investor Presentation Q3 2020/21 Results
INVESTOR PRESENTATION Q3 2020/21 RESULTS 17TH OF AUGUST 2021
Slide 2: Key Messages
KEY MESSAGES 1 Transition to single-use endoscopy market continues to accelerate New bronchoscopy safety communication from FDA now recommends sterilization of reusable endoscopes when available and adoption of single-use bronchoscopes when treating patients at increased risk of spreading infectio
Slide 3: Transition to single-use endoscopy market continues to accelerate
TRANSITION TO SINGLE-USE ENDOSCOPY MARKET 1 CONTINUES TO ACCELERATE U.S. medical device reports on endoscope related Expected single-use contamination and infections since 2014 market in 2025 Urology Bronchoscopy GI 2.000 1,880 USD ~2.5bn 1.500 1,027 1.000 Single-use market in 2021 713 500 USD 170 +
Slide 4: Business Update
‘| BUSINESS UPDATE
Slide 5: Strong growth despite COVID-19 fluctuations
STRONG GROWTH DESPITE COVID-19 FLUCTUATIONS 2 We have delivered a two-year Total company Visualization Core revenue CAGR of 14% compared to Q3 2018/19 2-year organic 2-year organic 2-year organic revenue CAGR revenue CAGR revenue CAGR +14% +36% Visualization continues to -1% grow rapidly with tw
Slide 6: Record Visualization volume is driven by new launches
RECORD VISUALIZATION VOLUME IS DRIVEN BY NEW LAUNCHES 2 Visualization continues its strong performance Endoscope units sold YTD exceeds FY 2019/20 Number of endoscopes sold YTD equal volume Endoscope units sold (‘000) +1,400 growth of 37% and exceeds total units sold in the entire full-year 2019/2
Slide 7: New growth platforms in Visualization continue to grow rapidly
NEW GROWTH PLATFORMS IN VISUALIZATION CONTINUES 2 TO GROW RAPIDLY aScope™ 4 RhinoLaryngo (ENT) aScope™ 4 Cysto, monthly global unit sales since launch Monthly global unit sales since launch Q1 Q3 Q3 Q3 2018/19 2020/21 2019/20 2020/21 7
Slide 8: Our aspiration is to become the most innovative single-use endoscopy player
OUR ASPIRATION IS TO BECOME THE MOST INNOVATIVE SINGLE-USE 3 ENDOSCOPY PLAYER Product Launch aView™ 2 Advance Commercially available Monitors aBox™ 2 Submitted for FDA clearance aScope™ 4 Broncho On target to introduce aScope™ BronchoSampler™ 20 new products VivaSight™ by 2022/23 Pulmonology VivaSig
Slide 9: We continue to execute on our extensive product pipeline
WE CONTINUE TO EXECUTE ON OUR EXTENSIVE PRODUCT PIPELINE 3 aScope™ Gastro & aBox™ 2 aScope™ 5 Broncho HD Single-use gastroscope system submitted for FDA Building on our market leadership with our clearance, entering 20m procedure market next-generation aScope™ Broncho system High performance e
Slide 10: We are building the most comprehensive airway offering in the market
WE ARE BUILDING THE MOST COMPREHENSIVE AIRWAY 3 OFFERING IN THE MARKET Commercially available 2009-2011 2012-2014 2015-2017 2018-2020 2021-2023 Video laryngoscope aScope™ 4 aScope™ 4 Broncho aScope™ 2 VivaSight™ DL/SL 1.0 Broncho Sampler Set aScope™ 4 aScope™ 1 aScope™ 3 aScope™ 3 Large VivaSight™ 2
Slide 11: Accelerating our Mexico plant to mitigate supply chain disruptions
ACCELERATING OUR MEXICO PLANT TO 3 MITIGATE SUPPLY CHAIN DISRUPTIONS The new plant in Mexico will be our largest single-use Visualization plant and reflects the scale of our ambitions and future growth expectations Accelerating the construction of the manufacturing plant in Mexico will secure capaci
Slide 12: Strengthening our management team and Board of Directors
WE ARE STRENGTHENING OUR MANAGEMENT TEAM AND BOARD OF DIRECTORS Executive leadership team new member Board of Directors new members proposal Brent Scott Michael del Prado President of Asia Pacific to join Ambu as Former Company Group Chairman of of October 1st, 2021 Johnson & Johnson Medical Dev
Slide 13: Financial Results and Outlook
FINANCIAL RESULTS AND OUTLOOK
Slide 14: Key financial results for Q3 2020/21
KEY FINANCIAL RESULTS FOR Q3 2020/21 REVENUE ORGANIC GROWTH DKK 973m 7% YTD 2020/21: DKK 2,987m YTD 2020/21: 16% ENDOSCOPES GROSS MARGIN 386,000 62.5% YTD 2020/21: 1,135,000 YTD 2020/21: 63.4% EBIT EBIT MARGIN DKK 88m 9.0% YTD 2020/21: DKK 336m YTD 2020/21: 11.2% 14
Slide 15: Organic sales growth by geography for Q3 2020/21
Organic revenue growth % ORGANIC SALES GROWTH BY GEOGRAPHY FOR Q3 2020/21 Global North America Europe Rest of the World +7% +32% -10% +7% organic growth organic growth organic growth organic growth 973m 418m 429m 126m DKK revenue DKK revenue DKK revenue DKK revenue 0% -1% 44% 47% 8% 68% -26% -13% 48
Slide 16: Disruption of the global supply chain impacts our financials
DISRUPTION OF THE GLOBAL SUPPLY CHAIN IMPACTS OUR FINANCIALS Airfreight and increased rates for container freight totals DKK 13m for Q3 and DKK 32m YTD. Effect on expected I EBIT-margin for FY 2020/21 is expected to be ~DKK 55m or ~1.4%-pts. We expect to continue air freight into 2021/22 In addition
Slide 17: Financial results Q3 2020/21
FINANCIAL RESULTS Q3 2020/21 Revenue / DKKm 6.000 7% organic growth 4.000 in Q3 2020/21 and 16% YTD with Visualization growing 29% YTD 2.000 3.567 2.606 2.820 1.013 1.001 973 0 FY 17/18 FY 18/19 FY 19/20 Q1 20/21 Q2 20/21 Q3 20/21 62.5% gross margin Q3 Change Change Q3 DKKm in Q3 2020/21. A relative
Slide 18: Cash flow, assets and debt Q3 2020/21
CASH FLOW, ASSETS AND DEBT Q3 2020/21 Q3 Q3 Change DKKm 20/21 19/20 in value DKK -113m Cash flow and ratios free cash flow Equal to -12% (20%) of Cash flow from operating activities 68 314 -246 Q3 2020/21 revenue Cash flow from investing activities before acquisitions -181 -127 -54 Free cash flow be
Slide 19: 2020/21 Financial Guidance
2020/21 FINANCIAL GUIDANCE Organic revenue growth Approx. 17% EBIT margin Approx. 10% Endoscope units sold +1.4m 19
Slide 20: Q&A
Q&A
Slide 21: Investor Contact Information
INVESTOR CONTACT INFORMATION Share Information Financial calendar Ambu A/S is listed on the stock exchange in 2021 Copenhagen under the symbol AMBU B 9 November Q4 2020/21 For further company information, please visit: 14 December Annual General Meeting 2020/21 www.ambu.com For full list of Investor